Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage-a systematic review and meta-analysis.

The mortality benefit noted in the observational data was not replicated by the ANNEXA-I trial, which noted a slight increase in mortality favoring the standard of care group that failed to reach statistical significance [ 17 ]. 3.5 Thrombotic complications Thrombotic complications were assessed in 13 studies ( n = 968 participants).

also in 6,035 other papers